JPWO2021069486A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021069486A5 JPWO2021069486A5 JP2022521144A JP2022521144A JPWO2021069486A5 JP WO2021069486 A5 JPWO2021069486 A5 JP WO2021069486A5 JP 2022521144 A JP2022521144 A JP 2022521144A JP 2022521144 A JP2022521144 A JP 2022521144A JP WO2021069486 A5 JPWO2021069486 A5 JP WO2021069486A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hantavirus
- infection
- rodent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU101430 | 2019-10-08 | ||
| LU101430 | 2019-10-08 | ||
| EP19203601.0 | 2019-10-16 | ||
| EP19203601 | 2019-10-16 | ||
| PCT/EP2020/078104 WO2021069486A1 (en) | 2019-10-08 | 2020-10-07 | Mek inhibitors for the treatment of hantavirus infections |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022551458A JP2022551458A (ja) | 2022-12-09 |
| JP2022551458A5 JP2022551458A5 (https=) | 2023-10-17 |
| JPWO2021069486A5 true JPWO2021069486A5 (https=) | 2023-10-17 |
| JP7802365B2 JP7802365B2 (ja) | 2026-01-20 |
Family
ID=73037924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521144A Active JP7802365B2 (ja) | 2019-10-08 | 2020-10-07 | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220378730A1 (https=) |
| EP (1) | EP4041212B1 (https=) |
| JP (1) | JP7802365B2 (https=) |
| KR (1) | KR20220079573A (https=) |
| CN (1) | CN114786659B (https=) |
| AU (1) | AU2020362953A1 (https=) |
| BR (1) | BR112022005896A2 (https=) |
| ES (1) | ES3045883T3 (https=) |
| MX (1) | MX2022004259A (https=) |
| WO (1) | WO2021069486A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11903917B2 (en) | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN116585294B (zh) * | 2023-06-05 | 2025-06-17 | 中国人民解放军空军军医大学 | 大黄素在制备抗汉滩病毒药物中的应用 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| CN101461805B (zh) * | 2009-01-16 | 2010-07-28 | 武汉大学 | 一种抗汉坦病毒药物阿比朵尔的用途 |
| BR112015007616B1 (pt) * | 2012-10-08 | 2022-08-09 | Atriva Therapeutics Gmbh | Uso de inibidores de mek em combinação com oseltamivir, e composição farmacêutica e seu uso |
| EA039897B1 (ru) | 2014-05-16 | 2022-03-24 | Атрива Терепьютикс Гмбх | Применение ингибитора мек для лечения коинфекции, включающей бактериальную инфекцию и инфекцию, вызванную вирусом гриппа |
| DE102014111892A1 (de) * | 2014-08-20 | 2016-02-25 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer Infektion mit dem Hantavirus |
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
-
2020
- 2020-10-07 EP EP20799621.6A patent/EP4041212B1/en active Active
- 2020-10-07 BR BR112022005896A patent/BR112022005896A2/pt unknown
- 2020-10-07 AU AU2020362953A patent/AU2020362953A1/en active Pending
- 2020-10-07 ES ES20799621T patent/ES3045883T3/es active Active
- 2020-10-07 US US17/767,186 patent/US20220378730A1/en active Pending
- 2020-10-07 MX MX2022004259A patent/MX2022004259A/es unknown
- 2020-10-07 CN CN202080084724.2A patent/CN114786659B/zh active Active
- 2020-10-07 JP JP2022521144A patent/JP7802365B2/ja active Active
- 2020-10-07 KR KR1020227013461A patent/KR20220079573A/ko active Pending
- 2020-10-07 WO PCT/EP2020/078104 patent/WO2021069486A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021069486A5 (https=) | ||
| CN114786659B (zh) | 用于治疗汉坦病毒感染的mek抑制剂 | |
| Frediansyah et al. | Remdesivir and its antiviral activity against COVID-19: A systematic review | |
| Agrawal et al. | Favipiravir: A new and emerging antiviral option in COVID-19 | |
| Acuña‐Castroviejo et al. | Clinical trial to test the efficacy of melatonin in COVID‐19 | |
| DK1982708T3 (en) | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanediol derivative as active ingredient and method of treating inflammatory bowel disease | |
| US20220125767A1 (en) | Thiazolide compounds for treating viral infections | |
| EP2799071B1 (en) | Levocetirizine and montelukast for the treatment of influenza and common cold | |
| Rebeaud et al. | SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment | |
| JP2013539790A (ja) | メマンチンを含む鎮咳組成物 | |
| KR102828536B1 (ko) | 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물 | |
| ES3039903T3 (en) | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections | |
| Mayer et al. | Chemoprophylaxis for HIV prevention: new opportunities and new questions | |
| KR20220111620A (ko) | 코비드-19 감염증의 예방 또는 치료용 약제학적 조성물 | |
| RU2843665C1 (ru) | Фармацевтическая композиция для профилактики или лечения эпидемического рнк-вирусного инфекционного заболевания | |
| Misra | A short review on important drugs under clinical trial against Covid-19 | |
| IT201600074507A1 (it) | Uso di xibornolo come agente attivo nel trattamento di infezioni virali | |
| Fregoso-Aguilar et al. | Natural Products with Therapeutic Action in Diabetes: A Coadjuvant Alternative Against COVID-19? | |
| Andrade et al. | Enough with the madness: a systematic review and meta-analysis of hydroxychloroquine for COVID-19 | |
| HK40090283A (en) | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections | |
| Vare et al. | Evaluation of antiulcer activity of diltiazem in rats | |
| KR20230098780A (ko) | 코로나바이러스에 대한 티아졸리드의 용도 | |
| HK40081976B (zh) | 用於预防或治疗流行性rna病毒传染病的药物组合物 | |
| Mossad | An Evidence-based approach to management of the common cold | |
| Tröger et al. | The place of neuraminidase inhibitors in the prophylaxis and treatment of influenza |